中文
EN
News Center
News Center
From “Breakout” to “Breakthrough”: VivaQuit® Honored Again at the Alibaba Health Pharmacy Annual Awards
Author：
VIWIT
Release Time：
2026-09-30
On September 16, 2026, Alibaba Health Pharmacy held its 10th anniversary celebration at InterContinental Hangzhou. At this milestone event, VivaQuit® (Varenicline Tartrate Tablets), viwit’s smoking-cessation brand, stood out among numerous brands on the strength of its sustained market growth and strong consumer recognition, receiving the 2026 Breakthrough Product of the Year award. Dr. Keene Wei, Chairman and President of viwit, attended the event and accepted the award.
Following its recognition as Breakout Brand of the Year in 2025, VivaQuit® once again took the stage at Alibaba Health Pharmacy’s annual awards ceremony. Its continued growth has been reflected in a series of notable milestones: the product has ranked No. 1 in sales on major e-commerce platforms for two consecutive years; it was selected among the first group of “New Service Consumption Brands” in Shandong Province and included in the “LuChain Premium Products” program of the Department of Industry and Information Technology of Shandong Province; and the project “Development and Industrial Application of Key Technologies for the Smoking-Cessation Drug Varenicline and Varenicline Tablets” received the Second Prize of the Shandong Provincial Science and Technology Progress Award. VivaQuit® has also been filed and approved in both China and the United States, making it one of the few smoking-cessation medicines from China to obtain marketing approvals in both markets.
From “Breakout” to “Breakthrough,” every step in VivaQuit®’s growth has been built on tangible progress, while reflecting viwit’s enduring commitment to “Innovation for a Better Life.” Underpinning this progress is an uncompromising commitment to quality. From raw materials to finished drug products, and from R&D through batch release, viwit has established a comprehensive quality management system covering the entire product lifecycle. This rigorous approach to quality has provided a solid foundation for VivaQuit® to build a strong position in a highly competitive market, while also giving viwit the capabilities and confidence to continue advancing into broader areas of pharmaceutical innovation.
Each award is both a recognition of what has been achieved and the beginning of a new chapter. Today, viwit’s business spans four major areas: innovative biologics, small-molecule drugs, active pharmaceutical ingredients (APIs), and borane products. The company continues to expand into advanced therapeutic areas, including targeted therapies, while actively developing emerging technologies such as in vivo cell engineering and gene therapy.
Looking ahead, viwit will continue to advance through scientific and technological innovation while keeping patient needs at the center of its work. The company will further strengthen strategic collaboration with industry partners such as Alibaba Health, with the goal of bringing more high-quality pharmaceutical and healthcare products to patients and families.